Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders

被引：0
|
作者：
Trapè, G [1 ]
Fianchi, L [1 ]
Lai, M [1 ]
Laurenti, L [1 ]
Piscitelli, R [1 ]
Leone, G [1 ]
Pagano, L [1 ]
机构：
[1] Univ Cattolica Sacro Cuore, Ist Ematol, Dept Hematol, I-00168 Rome, Italy
来源：
HAEMATOLOGICA | 2003年 / 88卷 / 02期
关键词：
lymphoproliferative disorders; rituximab; autaimmune hemolytic anemia;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We administered rituximab monoclonal antibody to five patients suffering from a lymphoproliferative CD20-positive disease associated, at diagnosis or after starting treatment, with autoimmune hemolytic anemia (AIHA). After treatment with rituximab we observed an improvement of AIHA in all cases, and, in one case, improvement of the autoimmune thrombocytopenia associated with the AIHA. There were no relevant side effects.
引用
收藏
页码：223 / 225
页数：3
相关论文
共 50 条
  • [31] Successful treatment of refractory Evan syndrome with anti-CD20 antibody (rituximab)
    Recht, M
    PEDIATRIC RESEARCH, 2003, 53 (04) : 299A - 299A
  • [32] Treatment of refractory chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody
    Guidi, S
    Bartolozzi, B
    Nozzoli, C
    Guglielmelli, P
    Lombardini, L
    Saccardi, R
    Vannucchi, AM
    Bosi, A
    BONE MARROW TRANSPLANTATION, 2006, 37 : S92 - S93
  • [33] B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorders (PT-LPD).
    Grefer, J
    Oertel, SH
    Hummel, M
    Serke, S
    Reinke, P
    Jonas, S
    Anagnostopoulos, L
    Arnold, R
    Dörken, B
    Riess, H
    BLOOD, 2001, 98 (11) : 132A - 132A
  • [34] Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
    Coiffier, B
    Haioun, C
    Ketterer, N
    Engert, A
    Tilly, H
    Ma, D
    Johnson, P
    Lister, A
    Feuring-Buske, M
    Radford, JA
    Capdeville, R
    Diehl, V
    Reyes, F
    BLOOD, 1998, 92 (06) : 1927 - 1932
  • [35] Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease
    Pham, PTT
    Wilkinson, AH
    Gritsch, HA
    Pham, PCT
    Miller, JM
    Lassman, CR
    Danovitch, GM
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (04) : 1178 - 1181
  • [36] Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome
    Yassa, SK
    Blessios, G
    Marinides, G
    Venuto, RC
    CLINICAL TRANSPLANTATION, 2005, 19 (03) : 423 - 426
  • [37] Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis
    Bhatia, A
    Ell, PJ
    Edwards, JCW
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) : 1099 - 1100
  • [38] Idiopathic membranous nephropathy (IMN) treatment with anti-CD20 monoclonal antibody Rituximab
    Lionaki, Sofia
    Sfikakis, Petros
    Theodoropoulou, Eleni
    Skalioti, Chrisanthi
    Iniotaki, Aliki
    Nakopoulou, Lydia
    Boletis, Ioannis
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 334 - 335
  • [39] Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia
    Hagberg, H
    Lundholm, L
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) : 609 - 611
  • [40] Rituximab: An anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura
    Aggarwal, A
    Catlett, JP
    SOUTHERN MEDICAL JOURNAL, 2002, 95 (10) : 1209 - 1212
12345